<?xml version="1.0" encoding="UTF-8"?>
<p>The beginning of the acute phase is marked by viral dissemination from the local site of replication to the primary sites of CHIKV infection in the host body (
 <xref rid="B24" ref-type="bibr">24</xref>). Hallmarks of the acute phase are peak viremia, manifestation of clinical symptoms, and production of neutralizing antibodies (
 <xref rid="B58" ref-type="bibr">58</xref>–
 <xref rid="B60" ref-type="bibr">60</xref>). The acute phase of CHIKD typically lasts for 7–14 days (
 <xref rid="B37" ref-type="bibr">37</xref>, 
 <xref rid="B61" ref-type="bibr">61</xref>, 
 <xref rid="B62" ref-type="bibr">62</xref>). In both humans and murine models, the general observation is that CHIKV-induced immunopathology is considered the primary mediator of damage and persistent pain.
</p>
